Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Lung Neoplasms 4Neoplasms 3Neoplasm Metastasis 3Pancreatic Neoplasms 2Brain Neoplasms 2Wilms Tumor 1Uterine Cervical Neoplasms 1Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Skin Neoplasms 1Sarcoma, Ewing 1Salivary Gland Neoplasms 1Rhabdomyosarcoma 1Osteosarcoma 1Neuroectodermal Tumors 1Medulloblastoma 1Liver Neoplasms 1Hematologic Neoplasms 1Glioma 1Ependymoma 1Disease 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Advanced Cancers 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

fludarabine 6Cyclophosphamide 5fludarabine phosphate 4Whole-Body Irradiation 4itacitinib 3angiotensin I (1-7) 3pembrolizumab 2Tacrolimus 2Olanzapine 2Nivolumab 2Magnetic Resonance Spectroscopy 2Ipilimumab 2INCB039110 2CTLA-4 Antigen 2Busulfan 2Brentuximab Vedotin 2Bendamustine Hydrochloride 2AP 1903 reagent 2tazemetostat 1tafasitamab 1ruxolitinib 1pomalidomide 1ofatumumab 1merphos 1lopinavir-ritonavir drug combination 1ivosidenib 1ibrutinib 1fedratinib 1enasidenib 1daratumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Hematologic Neoplasms × Erlotinib Hydrochloride × Clear all
NCT02355431 2019-03-08

Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Incyte Corporation

Phase 2 Withdrawn
Other hematologic neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡